GlassScriptPhysician profile
Carolyn Rutter
NPI 1912016767
$1,748.46
in general payments reported to CMS, 2019-2025
30 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $107 · 2021: $192 · 2022: $621 · 2023: $277 · 2024: $173 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $249.63 | 2022-2023 | Repatha |
| Theragenics Corporation | $206.86 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $190.84 | 2020-2025 | Lynparza |
| Varian Medical Systems, INC. | $115.30 | 2019 | |
| Merck Sharp & Dohme LLC | $110.42 | 2022-2025 | Keytruda, Keytruda Qlex, Welireg |
| Novocure INC. | $93.52 | 2019-2023 | Optune |
| Novartis Pharmaceuticals Corporation | $90.28 | 2019-2025 | |
| Intuitive Surgical, INC. | $84.93 | 2020 | |
| Incyte Corporation | $81.86 | 2022-2025 | Jakafi, Niktimvo |
| Elekta, INC. | $49.07 | 2022-2024 | Elekta Medical Linear Accelerator |
| Siemens Medical Solutions USA, INC. | $47.21 | 2022-2024 | Truebeam |
| Servier Pharmaceuticals LLC | $43.42 | 2022 | |
| Janssen Biotech, INC. | $32.18 | 2022-2023 | Erleada |
| Genentech USA, INC. | $31.80 | 2023-2025 | Tecentriq, Rozlytrek, Lunsumio |
| Daiichi Sankyo INC. | $30.90 | 2024-2025 | Injectafer, Enhertu |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $30.01 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $29.38 | 2021-2022 | |
| Blueprint Medicines Corporation | $29.08 | 2021-2024 | Ayvakit |
| Genzyme Corporation | $25.51 | 2025 | |
| Lilly USA, LLC | $20.32 | 2022 | |
| Sumitomo Pharma America, INC. | $17.37 | 2025 | Orgovyx |
| Sobi, INC | $17.27 | 2023 | |
| Myovant Sciences INC. | $17.04 | 2022 | |
| Adaptive Biotechnologies Corporation | $16.00 | 2022 | |
| Seagen INC. | $15.33 | 2023 | Padcev |
| Exelixis INC. | $15.20 | 2024 | Cabometyx |
| Stemline Therapeutics INC. | $15.09 | 2024 | Orserdu |
| Foundation Medicine, INC. | $14.99 | 2022 | |
| Pharming Healthcare, INC. | $14.46 | 2023 | Ruconest |
| Pharmacyclics LLC, An Abbvie Company | $13.19 | 2023 | Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carolyn Rutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.